Staging

While the Gleason score determines how aggressive the cancer is, staging the tumor allows doctors to see how far the cancer has spread. There are two different staging systems, the TNM staging system and the Whitmore-Jewett staging system. 
 
The TNM staging system: 
 
Tells you about the size of the tumor and where it has spread.
  • T1: Indicates that the cancer cannot be felt or seen by the naked eye
  • T2: Indicates that cancer is confined to the prostate gland
  • T3 to T4: Indicates that the cancer has spread past the prostate gland into surrounding tissues. 
If the cancer has spread to the lymph nodes, this will be indicated by an N 
  • N1: Indicates a small tumor in the lymph node
  • N2: Indicates a medium tumor in one node or several small tumors in several lymph nodes
  • N3: Indicates a large tumor in one or more lymph nodes
If the cancer has spread past the lymph nodes, it has metastasized and this is represented by an M
  • M1a: Indicates cancer has spread just past the nodes
  • M1b: Indicates cancer has spread into the bones
  • M1c: Indicates cancer has spread to other sites in the body
Whitmore-Jewett staging system:
 
In this system, the tumor is classified by letters (A to D). 
  • Stage A: Indicates that the cancer cannot be felt or seen by the naked eye  
  • Stage B: Indicates that the cancer is not detectable by the presence of a tumour 
  • Stage C: Indicates that the cancer has spread to surrounding tissues and vesicles of the prostate 
  • Stage D: Indicates that the cancer has spread to bones and organs throughout the body

For more information and support:





Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rocco Rossi to wrap up successful 5-year tenure as Prostate Cancer Canada CEO

September 7, 2017 - TORONTO, ON - With mixed emotions, longstanding Prostate Cancer Canada (PCC) President and CEO, Rocco Rossi, formally announced today that his time leading the organization will officially come to a close as of December 31, 2017.
More

Mutation in prostate tumours shown to change epigenetic identity, the make-up of DNA

(TORONTO, Canada - Aug 7, 2017) -- Prostate cancer researchers have mapped the impact of an acquired mutation that alters epigenetic identity, the make-up of DNA, in about 50% of patient tumour samples.
More

Movember Foundation and Prostate Cancer Canada team up to turn research into results

July 26, 2017 - TORONTO, ON - Continuing their longstanding tradition of partnering to fund high quality Canadian prostate cancer research, Prostate Cancer Canada (PCC) and The Movember Foundation today announced two new projects with very real potential to make a tangible difference in the lives of men living with aggressive forms of prostate cancer.
More


Click here for news archive